Darwin Global Management, Ltd. Immunovant, Inc. Transaction History

Darwin Global Management, Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $33.7 Million - $72.7 Million	1,818,371 New	1,818,371 $69.8 Million
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $618,980 - $1.11 Million	-65,849 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $1.75 Million - $6.62 Million	-133,420 Reduced 66.95%	65,849 $1.06 Million
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $7.25 Million - $10.5 Million	199,269 New	199,269 $9.2 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Darwin Global Management, Ltd., based on Form 13F filings with the SEC.

Stay updated on Darwin Global Management, Ltd. with notifications on news.